Good morning, myeloma world.

It's Monday, and the weekend definitely is over. The vigorous activity in our email inbox is making that eminently clear. But, with the week still so young, there isn't much new myeloma research for us to review with you. In fact, we have just two new studies that we'd like to discuss today.

Both studies are by European researchers who have compiled and analyzed retrospective data on some important topics.

One study out of Portugal looks …

Good morning, myeloma world.

We've got a lot of new myeloma-related research to cover today, so we'll get right down to business.

The first two studies we will review are related to autologous (own) stem cell transplantation.

One study looks at whether myeloma cells make their way into the infusion of a patient's own stem cells that a patient gets during the autologous transplant process. The study finds that, in some cases, myeloma cells do make it into the stem …

Good morning, myeloma world.

It's been a very chilly morning here at Myeloma Morning Headquarters. After teasing us with summerlike temperatures the past few weeks, Mother Nature has decided she's not done with the part of the thermometer below freezing.

We'll be focusing on two new research studies in today's report.

The first study looks at outcomes of allogeneic (donor) stem cell trans­plan­ta­tion for multiple myeloma. Using outcomes from a single U.S. treatment center, the study authors find that whether …

Updated results of a key Phase 1/2 trial testing the poten­tial new myeloma ther­a­py daratumumab were released this morning. The new results con­firm pre­vi­ous research indicating that single-agent dara­tu­mu­mab has notable activity as a multiple myeloma ther­apy.

Specifically, the results show that nearly one third of the trial par­tic­i­pants – who had received a median of five prior ther­a­pies – responded to single-agent dara­tumumab. The median time to disease pro­gres­sion was 3.7 months, and the esti­mated one-year over­all …

Results of a recent retrospective study conducted at the Mayo Clinic in­di­cate that the survival of patients with non­se­cre­tory multiple myeloma has improved over the last decade.

Nonse­cre­tory multiple myeloma is a rare form of myeloma in which a patient’s disease cannot be diagnosed or tracked by the presence of monoclonal protein in the blood or urine.  This is not the case for most myeloma patients, who have “se­cre­tory” disease which can be tracked using lab results such as a …

A recently published study may change the goals many myeloma special­ists use to make treatment decisions for newly diagnosed myeloma pa­tients planning on having a stem cell transplant.

The study also has potentially broader implications. Indeed, it may influ­ence ongoing debate on a fundamental controversy about how multiple myeloma, in general, should be treated.

The authors of the new study looked at data for 539 myeloma patients who failed to achieve even a partial response to their initial (induction) treat­ment regimen …

The results of a recently published study show that, among newly diag­nosed myeloma patients, African-Americans are less likely than white Americans to have the four most common myeloma-related chro­mo­somal ab­nor­mal­ities.

The authors of the study investigated how often the chro­mo­somal ab­nor­mal­ities t(11;14), t(4;14), del(13q), and del(17p) were present in two dif­fer­ent groups of newly diagnosed myeloma patients. One group con­sisted of African-Americans, the other of white Americans.

Each of the four ab­nor­mal­ities occurred less frequently in the African-American patients.

In …